Venus Concept Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Venus Concept Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $64.83M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $76.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $99.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $105.62M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $78.01M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $110.41M | Dec 22, 2021 |
| FY2018 | Dec 31, 2018 | $6.66M | Mar 20, 2019 |
| FY2018 | Sep 30, 2018 | $4.82M | Mar 20, 2019 |
| FY2018 | Jun 30, 2018 | $5.48M | Mar 20, 2019 |
| FY2018 | Mar 31, 2018 | $5.01M | Mar 20, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $44.31M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $52.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $65.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $74.09M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $51.39M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $76.65M | Dec 22, 2021 |
| FY2018 | Dec 31, 2018 | $2.57M | Mar 20, 2019 |
| FY2018 | Sep 30, 2018 | $2.16M | Mar 20, 2019 |
| FY2018 | Jun 30, 2018 | $2.96M | Mar 20, 2019 |
| FY2018 | Mar 31, 2018 | $1.82M | Mar 20, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($47.00M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($37.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($43.70M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($23.01M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($81.71M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($40.62M) | Dec 22, 2021 |
| FY2018 | Dec 31, 2018 | ($7.98M) | Mar 20, 2019 |
| FY2018 | Sep 30, 2018 | ($7.07M) | Mar 20, 2019 |
| FY2018 | Jun 30, 2018 | ($6.24M) | Mar 20, 2019 |
| FY2018 | Mar 31, 2018 | ($7.43M) | Mar 20, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($27.18M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($28.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($34.88M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.77M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($67.90M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($30.28M) | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | ($3.37M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($17.28M) | Mar 20, 2019 |
| FY2018 | Dec 31, 2016 | ($18.93M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2015 | ($20.53M) | Mar 5, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.69M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $8.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.95M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $3.02M | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | $2.71M | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | $2.64M | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | $9.65M | Mar 27, 2023 |
| FY2022 | Sep 30, 2021 | $2.23M | Mar 27, 2023 |
| FY2022 | Jun 30, 2021 | $2.35M | Mar 27, 2023 |
| FY2022 | Mar 31, 2021 | $2.41M | Mar 27, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($11.07M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($12.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($26.98M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.77M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($28.65M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($39.60M) | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | ($33.65M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($19.26M) | Mar 20, 2019 |
| FY2018 | Dec 31, 2016 | ($16.16M) | Mar 20, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $123.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $116.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $336.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $512.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $291.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.12M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.16M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $229.0K | Mar 20, 2019 |
| FY2018 | Dec 31, 2016 | $1.17M | Mar 20, 2019 |
| FY2017 | Dec 31, 2015 | $456.0K | Mar 5, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $68.18M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $93.65M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $125.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $157.37M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $160.53M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $191.13M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $125.13M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $32.97M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $19.50M | Mar 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $65.35M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $107.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $116.64M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $115.78M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $116.76M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $114.45M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $88.68M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $19.78M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $27.31M | Mar 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.37M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($14.02M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.09M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $40.94M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $44.23M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $74.18M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $32.43M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $13.19M | Mar 20, 2019 |
| FY2018 | Dec 31, 2016 | ($143.54M) | Mar 20, 2019 |
| FY2018 | Dec 31, 2015 | ($122.21M) | Mar 20, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $27.45M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $2.60M | Mar 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($308.90M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($261.90M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($224.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($180.41M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($157.39M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($75.69M) | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | ($35.07M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($164.49M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($146.65M) | Mar 5, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.27M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $5.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.57M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $30.88M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $34.30M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $15.67M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | $6.74M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $23.55M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $11.91M | Mar 5, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $36.18M | Dec 22, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (71) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (68) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | (4) | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 30, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (71) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (68) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | (4) | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 30, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 709,130 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 552,205 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 5.16M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 63.98M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 53.55M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 28.69M | Dec 22, 2021 |
| FY2019 | Dec 31, 2018 | 4.77M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 28.94M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 1.62M | Mar 5, 2018 |